Publications by authors named "Del Miller"

Claim this Profile
L
Longitudinal study of inflammation and relapse in schizophrenia.
Brian J Miller, Henrique Lemos, Nina R Schooler, Donald C Goff, Alexander Kopelowicz, Del D Miller

Schizophr Res· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Predicting relapse in schizophrenia: Is BDNF a plausible biological marker?
Anilkumar Pillai, Nina R Schooler, Diya Peter, Stephen W Looney, Donald C Goff, Del D Miller

Schizophr Res· March 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of Injectable and Oral Antipsychotics in Relapse Rates in a Pragmatic 30-Month Schizophrenia Relapse Prevention Study.
Peter F Buckley, Nina R Schooler, Donald C Goff, Alex Kopelowicz, John Lauriello, Del D Miller

Psychiatr Serv· December 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of SGA oral medications and a long-acting injectable SGA: the PROACTIVE study.
Peter F Buckley, Nina R Schooler, Donald C Goff, John Hsiao, Alexander Kopelowicz, Del D Miller

Schizophr Bull· March 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evidence for accelerated vascular aging in bipolar disorder.
Simrit K Sodhi, Jonathan Linder, Catherine A Chenard, Del D Miller, William G Haynes

J Psychosom Res· September 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Feasibility and pilot efficacy results from the multisite Cognitive Remediation in the Schizophrenia Trials Network (CRSTN) randomized controlled trial.
Richard S E Keefe, Sophia Vinogradov, Alice Medalia, Peter F Buckley, Stanley N Caroff, Del D Miller

J Clin Psychiatry· July 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Systematic Review and Meta-analysis of Pharmacological Interventions for Weight Gain from Antipsychotics and Mood Stabilizers.
Jess G Fiedorowicz, Del D Miller, Jeffrey R Bishop, Chadi A Calarge, Vicki L Ellingrod

Curr Psychiatry Rev· February 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Concomitant psychotropic medication use during treatment of schizophrenia patients: longitudinal results from the CATIE study.
Miranda Chakos, Javendra K Patel, Robert Rosenheck, Ira D Glick, Mark B Hammer, Alexander Miller, Del Miller

Clin Schizophr Relat Psychoses· October 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Factors associated with the prescribing of olanzapine, quetiapine, and risperidone in patients with bipolar and related affective disorders.
Maithri Prabhakar, William G Haynes, William H Coryell, Elizabeth A Chrischilles, Del D Miller

Pharmacotherapy· August 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Predictors of risperidone and 9-hydroxyrisperidone serum concentration in children and adolescents.
Chadi Albert Calarge, Del D Miller

J Child Adolesc Psychopharmacol· April 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment outcomes of patients with tardive dyskinesia and chronic schizophrenia.
Stanley N Caroff, Vicki G Davis, Del D Miller, Sonia M Davis, Robert A Rosenheck

J Clin Psychiatry· March 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Association between type-three metabotropic glutamate receptor gene (GRM3) variants and symptom presentation in treatment refractory schizophrenia.
Jeffrey R Bishop, Del D Miller, Vicki L Ellingrod, Timothy Holman

Hum Psychopharmacol· January 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacogenetics and schizophrenia.
Adriana Foster, Del D Miller, Peter Buckley

Clin Lab Med· December 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Genomewide association study of movement-related adverse antipsychotic effects.
Karolina Aberg, Daniel E Adkins, József Bukszár, Bradley T Webb, Stanley N Caroff, Del D Miller

Biol Psychiatry· February 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antipsychotic dose equivalents and dose-years: a standardized method for comparing exposure to different drugs.
Nancy C Andreasen, Marcus Pressler, Peg Nopoulos, Del Miller, Beng-Choon Ho

Biol Psychiatry· February 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A candidate gene study of Tardive dyskinesia in the CATIE schizophrenia trial.
Huei-Ting Tsai, Stanley N Caroff, Del D Miller, Joseph McEvoy, Jeffrey A Lieberman

Am J Med Genet B Neuropsychiatr Genet· January 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Population pharmacokinetics of perphenazine in schizophrenia patients from CATIE: impact of race and smoking.
Yuyan Jin, Bruce G Pollock, Kim Coley, Del Miller, Stephen R Marder

J Clin Pharmacol· January 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Variants of the dopamine D2 receptor gene and risperidone-induced hyperprolactinemia in children and adolescents.
Chadi A Calarge, Vicki L Ellingrod, Laura Acion, Del D Miller, Jessica Moline

Pharmacogenet Genomics· May 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Population pharmacokinetic analysis for risperidone using highly sparse sampling measurements from the CATIE study.
Yan Feng, Bruce G Pollock, Kim Coley, Stephen Marder, Del Miller

Br J Clin Pharmacol· November 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Extrapyramidal side-effects of antipsychotics in a randomised trial.
Del D Miller, Stanley N Caroff, Sonia M Davis, Robert A Rosenheck, Joseph P McEvoy

Br J Psychiatry· October 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Elevated prevalence of obesity, metabolic syndrome, and cardiovascular risk factors in bipolar disorder.
Jess G Fiedorowicz, Narasimha M Palagummi, Valerie L Forman-Hoffman, Del D Miller, William G Haynes

Ann Clin Psychiatry· September 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The effectiveness of antipsychotic medications in patients who use or avoid illicit substances: results from the CATIE study.
Marvin S Swartz, H Ryan Wagner, Jeffrey W Swanson, T Scott Stroup, Joseph P McEvoy, Del D Miller

Schizophr Res· March 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sex, race, and smoking impact olanzapine exposure.
Kristin L Bigos, Bruce G Pollock, Kim C Coley, Del D Miller, Stephen R Marder

J Clin Pharmacol· February 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparative assessment of the incidence and severity of tardive dyskinesia in patients receiving aripiprazole or haloperidol for the treatment of schizophrenia: a post hoc analysis.
Del D Miller, James M Eudicone, Andrei Pikalov, Edward Kim

J Clin Psychiatry· December 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2006 update.
Troy A Moore, Robert W Buchanan, Peter F Buckley, John A Chiles, Robert R Conley, Del D Miller, Alexander L Miller

J Clin Psychiatry· November 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis